NCT02261207View on ClinicalTrials.gov

Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

October 31, 2017

Study Completion Date

March 31, 2018

Conditions
Solitary Fibrous Tumor
Interventions
DRUG

Axitinib

Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.

Trial Locations (1)

20133

Fondazione IRCCS Istituto Naazionale dei Tumori, Milan

All Listed Sponsors
lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

NCT02261207 - Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor | Biotech Hunter | Biotech Hunter